Judges Scientific: The Order Book Blinks First
A brutal H1 (−21% revenue, −72% EPS) hidden beneath an order-intake turn from −18% to −1% — powered by a China VAT quirk, not tariffs
JDG.L · Earnings Call · 2026-09-23
A half to forget, a chart to remember
Judges Scientific is a £246m buy-and-build compounder in scientific instruments — 19 separate P&Ls, deliberately asset-light, high cash conversion. H1 2026 was ugly: revenue down 21%, like-for-like down 13% ex the one-off Geotek coring expedition, adjusted EPS down 72%. CEO Tim Prestidge didn't soften it: “our revenue was down 21% compared to prior-year. That would be 13% on a like-for-like basis” — Tim Prestidge, CEO · 2026-09-23.
But the entire call orbits one thing: order intake. It's the top-ranked keyword by a wide margin, and management built a whole slide around it — the red line (internal sales budget), the black line (trailing 12-month orders), and the green line (last four months annualized). That trio is genuinely company-unique; you won't find this framing in peers' transcripts. The green line tracking at or above budget is the tactile signal management wants investors to feel.
The inflection is the whole story
Q1 order intake was −18%, the half closed at −12%, and by the time of the call “like-for-like order intake year-to-date is now almost at parity” — Brad Ormsby, CFO · 2026-09-23. CFO Brad Ormsby's green line “has been at around or a bit above the budget level for at least a month” — Brad Ormsby, CFO · 2026-09-23 — effectively five months of budget-level orders. That is the difference between a cyclical trough and a structural break, and it changed the tone from defensive to confident.
The improved order momentum, we are not characterizing it as a general sort of rising tide, if you like, or a general recovery in the scientific instrumentation market.
What's actually driving it is narrow and industrial: big-ticket orders across semiconductor, battery technology and industrial research. Meanwhile the headwinds are unchanged — US federal funding uncertainty persists with 2027 budget cuts being floated, and the next Geotek coring expedition now slides to no earlier than 2028. This is a company-specific demand story, not a market one. And the margin math cuts both ways: high operational leverage turned a 21% revenue drop into a two-thirds profit drop, even as cash conversion held at 90%.
What's conspicuously absent: tariffs and AI
Here the contrast bites. Scan today's other reporters and the dominant shared theme is the tariff refund — Cracker Barrel, MillerKnoll and KMD all book tariff-refund benefits. Judges doesn't mention tariffs once. Its China problem is instead a Chinese VAT/tax-exemption quirk: “this is not something which is specific to Judges” — Tim Prestidge, CEO · 2026-09-23, a ~13% exemption process slowed by the new five-year plan. Management frames it as delay, not loss — some orders now being asked for again, with recovery expected into 2027.
Equally absent is the global AI-adjacent industrial wave that dominates the tape. Ian Wilcock's only artificial-intelligence reference is modest — putting 23 people through AI apprenticeships for SME manufacturing. No hyperscaler customer, no data-center derivative. For a UK scientific-instrument roll-up this is honest, but it means Judges rides none of the momentum trades and suffers none of their unwinds. Is this a company riding a broader wave? No — it is idiosyncratic, which cuts both ways.
Capital allocation under the microscope
Three things converged this half. First, CFO succession: Ormsby retires after 11 years, giving 12 months' notice — a real loss for a story that leans on financial discipline and a strong decentralization culture.
Second, the buyback debate. Asked whether the board would add opportunistic buybacks alongside its 10% dividend progression, Ormsby was blunt: “the use of increasing debts in order to achieve share buybacks outside of everything else we are doing is necessarily an excellent use of our capital allocation at the moment” — Brad Ormsby, CFO · 2026-09-23. Deleverage first. The interim dividend still rose 10% to 36p, on cover of just 1.1x that management openly concedes is unsustainable in isolation and should mechanically improve in H2.
Third, the deal pool. No acquisitions in H1 — already a two-year dry spell. But Tim insists the opportunity set is improving, and crucially, seller multiples aren't softening: “we're not seeing any sort of reduction or deterioration in that sense of the multiple expectations” — Tim Prestidge, CEO · 2026-09-23. Still 4–6x EBIT, cash and debt funded.
The trade-off, plainly
Judges is a self-help turnaround dressed up as macro victim. The £2m of cost-out at underperforming businesses, the 10% dividend hike, ROTIC sliding to ~13%, and an 18% effective tax rate courtesy of the Patent Box scheme all point to a business choosing investments in organic growth over short-term optics. Banking facilities were extended two years to July 2030, and the small defined-benefit pension scheme was fully bought out in August — tidying the balance sheet.
With H2 needing roughly £1.60 of EPS against last year's ~£1.40, the year hinges on execution of a Q4-weighted order book. Management says the risks are "predominantly within our control." That is the bet. There is no price-tape confirmation available here — the order-intake chart is the only scoreboard, and for the first time in several quarters, it is finally ticking up.